Biomarkers Have Potential to Shape Treatment of RCC

Reviewing the Choice of First-Line Combinations for Clear Cell RCC and Other Histologies

POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?

Choosing Frontline RCC Therapy After Detecting Metastases in Patient Under Observation

Comparing Physician Experience With Trial Data for Frontline RCC Regimens

Reviewing Updated Survival and Subgroup Data of CheckMate9ER for RCC

Physicians Discuss Potential of Frontline Triplet Regimens for RCC

Opinions on the Optimal Role of Ipilimumab/Nivolumab in RCC

Selecting IO/TKI Therapy for mRCC Based on Patient Profile

Real-World Factors Influence Choice of IO/TKI Regimen for mRCC

Risk Group Data Raises Questions on Choice of Frontline Therapy in RCC

Physicians Discuss Counseling on Immunotherapy Discontinuation in RCC

Updated Data Supports Use of Nivolumab + Cabozantinib in Advanced ccRCC

Nivolumab plus Cabozantinib Continues to Show Benefit in Advanced RCC

Risk Stratification Influences Approach in Frontline Advanced RCC Care

Treatment Selection and Dosing Strategies Based on Trial Data in RCC

Updated Data Shows Durable Efficacy of Cabozantinib/Nivolumab in mRCC

Management of Serious Toxicities with Cabozantinib/Nivolumab in mRCC

Risk Stratification Influences Choice of Frontline IO/TKI Regimen in mRCC

Evolving Evidence Guides Treatment Selection for Favorable-Risk mRCC

Deciding Factors for Front-Line Therapy in Metastatic RCC

Comparing Choices for IO/TKI Combinations in Advanced RCC

Comparing Long-Term Data for IO/IO and IO/TKI in Favorable-Risk mRCC

Frontline Cabo/Nivo in RCC Supported by Risk Status, Metastasis Analyses

GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC

Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy

Participants Discuss Differences in Treatment in First-Line mRCC

Considering How Favorable Risk Affects Treatment in ccRCC

Primary Progressive Disease Rate Supports IO/TKI Use in Frontline mRCC

What's Next for Frontline Metastatic RCC Therapy

Now Viewing

Biomarkers Have Potential to Shape Treatment of RCC

Alan Tan, MD, assistant professor of medicine in the division of hematology and oncology at Vanderbilt University Medical Center, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell carcinoma (RCC).

In addition to the development of new targeted therapies, studying biomarkers is another approach to improve outcomes in patients with RCC. Tan says the KIM-1 (kidney injury molecule-1) protein found in plasma is the newest innovation in blood-based biomarkers for RCC. He suggests it could be combined with other biomarkers such as circulating tumor DNA (ctCNA) and methylation signatures to predict outcomes such as low vs high risk of disease recurrence after resection of localized RCC.

In addition, translational research has led to prospective studies on the use of biomarkers in the metastatic setting to select IO (immunotherapy) and TKI (tyrosine kinase inhibitor) combinations. The phase 2 multicenter OPTIC RCC study (NCT05361720) is assigning patients to receive ipilimumab (Yervoy) plus nivolumab (Opdivo) or nivolumab plus cabozantinib (Cabometyx) based on biologic clusters defined by RNA sequences in tumor specimens. Tan says that this study could show prospectively which patients should receive IO/IO or IO/TKI.

TRANSCRIPTION

0:10 | There's a lot of excitement to come with more translational research. I think biomarkers are incredibly exciting. Whether it's—KIM-1 is the newest innovation that we have, and I think we look forward to how we can apply that KIM-1 biomarker, maybe in combination with other biomarkers like ctDNA or methylation signatures. We do have some translational prospective studies that we're looking at like OPTIC RCC. How does the angiogenic or T-cell enriched clusters actually help us predict who should be allocated to IO/IO vs IO/TKI?